Prediction of the Responsiveness to Treatment with Erythropoiesis‐Stimulating Factors: A Prospective Clinical Study in Patients with Solid Tumors

• Published in: The oncologist (Dayton, Ohio) Ohio), 2007-06, Vol.12 (6), p.748-755
• Main Authors: Steinmetz, Tilman, Hellmich, Martin, Neise, Michael, Aldaud, Ali, Lerchenmüller, Christian, Tsamaloukas, Antonis, Fandel, Francoise, Weiligmann, Christoph, Totzke, Uwe, Schmitz, Stephan
• Format: Article
• Language: English
• Subjects: Aged; Anemia; Anemia - blood; Anemia - drug therapy; Anemia - etiology; Corresponding receiver operating characteristic curve; Erythropoietic proteins; Erythropoietin - blood; Erythropoietin - therapeutic use; Female; Hematinics; Hemoglobins - metabolism; Humans; Male; Middle Aged; Neoplasms - complications; Predictive factors; Prognosis; Prospective Studies; Recombinant Proteins; ROC Curve; Treatment Outcome
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.12-6-748

Objective. Treatment with erythropoiesis‐stimulating factors (ESFs) can ameliorate anemia associated with cancer and chemotherapy. However, half of anemic cancer patients do not respond even to high doses. To determine factors that are predictive of a treatment response, a multicenter, prospective study was performed. Patients and Methods. Investigated factors were baseline erythropoietin, reticulocytes and soluble transferrin receptor (sTfR) after 2 weeks, and reticulocytes and hemoglobin after 4 weeks. Anemic patients with solid tumors received 150 μg/week of darbepoetin concomitantly with chemotherapy. The dose was doubled if hemoglobin did not increase by >1 g/dl after 4 weeks. Patients were considered responders if hemoglobin increased by ≥2 g/dl or reached a level ≥12 g/dl within 8–12 weeks. Results. In total, 196 patients were enrolled; 61% of the intention‐to‐treat (ITT) and 68% of the per‐protocol population were responders. In the ITT population, the hemoglobin increase after 4 weeks indicated an 11‐fold higher chance of response (odds ratio, 11.0; 95% confidence interval [CI], 5.1–23.6; sensitivity, 88%; specificity, 60%). In a multiple logistic regression model including all factors, the area under the receiver operating characteristic curve was 0.78 (95% CI, 0.71–0.84). The combination of sTfR after 2 weeks and hemoglobin after 4 weeks was as predictive as the combination of all five tested factors. Conclusion. So far, an early hemoglobin increase remains the single most predictive factor for response to ESF treatment. In contrast to anemic patients with lymphoproliferative malignancies, serum erythropoietin had little predictive value in patients with solid tumors. Disclosure of potential conflicts of interest is found at the end of this article.